fentanyl iontophoretic transdermal process and butabarbital equally boost sedation. Stay away from or Use Alternate Drug. Restrict use to people for whom option therapy options are insufficient

This medication passes into breast milk and may have unwanted consequences on the nursing toddler. Consult your doctor prior to breastfeeding. Withdrawal signs and symptoms might take place for those who quickly halt using this medication. Supplemental Facts

butabarbital will lessen the extent or influence of eltrombopag by impacting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.

butabarbital will decrease the extent or result of diazepam intranasal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. Powerful or average CYP3A4 inducers could enhance rate of diazepam elimination; as a result, efficacy of diazepam may be decreased.

The effect in the resultant lowered blood levels of griseofulvin on therapeutic response hasn't been founded. Nonetheless, It might be preferable to prevent concomitant administration of these medicine.

Often consult your Health care provider to make certain the knowledge displayed on this site applies to your own conditions.

HydrOXYzine: May possibly enhance the CNS depressant effect of Barbiturates. Administration: Consider a lower within the barbiturate dose, as ideal, when employed along with hydroxyzine. With concurrent use, check here keep an eye on people carefully for abnormal response to the combination. Take into account therapy modification

butabarbital will lessen the extent or influence of triazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.

butabarbital will lessen the extent or result of vincristine liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.

butabarbital will reduce the extent or impact of darunavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.

Felbamate: May perhaps enhance the serum concentration of Barbiturates. Barbiturates might lessen the serum focus of Felbamate. Management: Watch for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose amplified, or decreased concentrations/results if felbamate is discontinued/dose lessened. Make reference to phenobarbital dosing suggestions for patients receiving that agent. Monitor therapy

butabarbital will minimize the extent or effect of lorlatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

butabarbital will decrease the level or impact of phenytoin by affecting hepatic enzyme CYP2C9/ten metabolism. Use Warning/Keep an eye on.

butabarbital will reduce the extent or influence of lonafarnib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is often a delicate CYP3A4 substrate. Coadministration with solid or reasonable CYP3A4 inducers is contraindicated.